Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Lymph node staging in colorectal cancer (CRC) is established by histological examination. Molecular techniques, such as one-step nucleic acid amplification (OSNA), have been recommended by NICE1 for intraoperative sentinel node assessment in breast cancer. OSNA is a relatively novel and simple molecular technique that uses a reverse-transcriptase loop-mediated isothermal amplification (RT-LAMP) reaction to detect tumour specific (CK19) mRNA in lymph nodes. We aim to provide unbiased data on the diagnostic accuracy of OSNA in detecting CRC nodal metastases and feedback the practicalities of running such a service in an National Health Service (NHS) cellular pathology department.
Consent was sought from consecutive patients undergoing elective resection for any stage CRC over a 14-month period (November 2013–December 2014). Stented tumours and perforated cases were excluded.
Resected specimens were received fresh, inked according to standard guidelines and lymph nodes were dissected. Each harvested node was bisected—one half was fixed in 10% formalin for routine histology and the other was snap-frozen in liquid nitrogen and stored at −80°C for OSNA processing. The remaining specimen was fixed and subsequently dissected for standard histology. OSNA assaying was performed as per manufacturers' instructions. Lymph nodes weighing >0.05 g were analysed in a single assay and those <0.05 g were combined for processing. Nodes were homogenised in lysis buffer (Lynorhag; Sysmex) and …
Contributors RC oversaw the histological comparison study and ran the OSNA assays. LMW carried out the histopathology. The other authors managed the patient recruitment, led by TY. RC drafted the manuscripts and all authors contributed to the editing.
Funding The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Oxford Colon Cancer Trust (OCCTOPUS) and the Bowel Disease Research Foundation (BDRF).
Competing interests None declared.
Ethics approval Oxfordshire Research and Ethics Committee A (reference 10/H0724/13).
Provenance and peer review Not commissioned; externally peer reviewed.